Cellestia

Cellestia Biotech AG is a clinical-stage biotechnology company that develops first-in-class therapies designed to modulate gene expression for the treatment of various severe diseases. The organization primarily focuses on advancing novel drug candidates that specifically target transcription factors to address complex medical conditions, particularly within the oncology sector. To support the continued expansion of its clinical pipeline, the enterprise secured CHF 20 million during a Series B equity financing round. This venture capital funding is directly allocated toward progressing the company's ongoing Phase I clinical trial programs into more advanced Phase II development stages. The corporate leadership and advisory team includes Chief Executive Officer Michael Bauer, alongside board members Guido Guidi and Robert Karsunky, both of whom bring extensive prior executive management experience from their respective tenures at Novartis Pharma and its oncology division.